Neuphoria Therapeutics (NEUP) Change in Accured Expenses (2023 - 2026)
Neuphoria Therapeutics (NEUP) reported Change in Accured Expenses of -$1.2 million for Q1 2026, down 414.08% year-over-year from $375529.0 in Q1 2025, and up 26.41% on a QoQ basis from -$1.6 million in Q4 2025.
Neuphoria Therapeutics (NEUP) has 4 years of Change in Accured Expenses data on file, last reported at -$1.2 million in Q1 2026.
- Quarterly Change in Accured Expenses fell 414.08% year-over-year to -$1.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $201135.0 (up 171.96% YoY) and the FY2025 annual result came in at $1.5 million, up 435.05% from the prior year.
- Change in Accured Expenses improved to -$1.2 million in Q1 2026 per NEUP's latest filing, from -$1.6 million in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $2.3 million in Q2 2025 and bottomed at -$1.6 million in Q4 2025.
- The 4-year median for Change in Accured Expenses is -$367583.0 (2024), against an average of -$27222.1.
- The widest annual swing landed in 2025, when Change in Accured Expenses surged 354.01%; it then tumbled 414.08% in 2026.
- Tracing NEUP's Change in Accured Expenses over 4 years: stood at $957800.0 in 2023, then tumbled by 182.1% to -$786378.0 in 2024, then sank by 103.81% to -$1.6 million in 2025, then climbed by 26.41% to -$1.2 million in 2026.
- Per Business Quant, the three latest NEUP Change in Accured Expenses figures stand at -$1.2 million (Q1 2026), -$1.6 million (Q4 2025), and $718261.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 931,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 70.50 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 107.70 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -176.03 Mn |
| 10 | Neuphoria Therapeutics | 28.35 Mn | 8.95 Mn | - | -1.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.18 Mn |
| Mar 31, 2026 | -1.18 Mn |
| Dec 31, 2025 | -1.60 Mn |
| Dec 31, 2025 | -1.60 Mn |
| Sep 30, 2025 | 718,261.00 |
| Sep 30, 2025 | 718,261.00 |
| Jun 30, 2025 | 2.27 Mn |
| Jun 30, 2025 | 2.27 Mn |
| Mar 31, 2025 | 375,529.00 |
| Mar 31, 2025 | 375,529.00 |
| Dec 31, 2024 | -786,378.00 |
| Dec 31, 2024 | -786,378.00 |
| Sep 30, 2024 | -367,583.00 |
| Sep 30, 2024 | -367,583.00 |
| Jun 30, 2024 | 498,908.00 |
| Jun 30, 2024 | 498,908.00 |
| Mar 31, 2024 | -474,109.00 |
| Mar 31, 2024 | -474,109.00 |
| Dec 31, 2023 | 957,800.00 |
| Dec 31, 2023 | 957,800.00 |
| Sep 30, 2023 | -704,745.00 |
| Sep 30, 2023 | -704,745.00 |